Want to see BAYRY full AI Analyst Report?
BAYRY Stock Chart & Stats
$14.30
$0.26(1.98%)
At close: 4:00 PM EDT
$14.30
$0.26(1.98%)
Day’s Range― - ―
52-Week Range$7.54 - $15.27
Previous CloseN/A
Volume684.76K
Average Volume (3M)196.59K
Market Cap
$55.73B
Enterprise Value$93.55K
Total Cash (Recent Filing)$4.29B
Total Debt (Recent Filing)$38.42B
Price to Earnings (P/E)―
Beta0.37
Next Earnings
Nov 03, 2026EPS Estimate
0.14Next Dividend Ex-DateN/A
Dividend Yield0.23%
Share Statistics
EPS (TTM)-0.42
Shares Outstanding3,929,696,000
10 Day Avg. Volume184,348
30 Day Avg. Volume196,593
Financial Highlights & Ratios
PEG Ratio-0.29
Price to Book (P/B)1.40
Price to Sales (P/S)0.83
P/FCF Ratio18.08
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$15.50Price Target Upside8.39% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)1.3
Revenue Forecast (FY)$52.93B
Bulls Say, Bears Say
Bulls Say
Crop Science Margin ExpansionSustained margin expansion in Crop Science reflects a shift to higher‑value seeds & traits and licensing revenue, improving structural profitability. Higher divisional margins support group cash generation through commodity cycles and make Crop Science a durable earnings driver over the next 2‑6 months.
Capital Transactions Reducing LeverageA committed EUR 3bn equity injection plus successful bond issuance materially improves funding flexibility and reduces near‑term refinancing risk. These structural capital moves lower net debt and increase runway to manage litigation cash needs without impairing core operations or R&D spending.
Pharma Product Growth And ResilienceStrong growth in specific marketed therapies shows successful portfolio rejuvenation: high‑growth assets offset legacy declines, supporting steady Pharma margins. Durable product-level growth reduces dependence on single franchises and underpins mid‑term revenue stability as pipeline assets progress.
Bears Say
Elevated Leverage And Limited FlexibilitySustained high leverage restricts strategic optionality and increases sensitivity to earnings volatility; negative ROE and sizable net debt amplify refinancing and interest risks. Over the coming months, elevated leverage limits capacity to absorb shocks or pursue large M&A without further funding actions.
Negative Free Cash Flow From Litigation PayoutsLarge litigation cash outflows materially weaken free cash flow conversion even while operating cash flow remains positive. This structural drain forces reliance on external financing and capital transactions, constraining investment capacity and increasing execution risk for strategic priorities over the medium term.
Eylea Franchise Under Biosimilar PressureA steep decline in a core ophthalmology franchise signals structural revenue erosion from biosimilar competition. Losing scale in a high‑margin product reduces Pharma margin resilience and raises near‑term replacement needs, increasing pressure on R&D and launch execution to sustain top‑line over months ahead.
Bayer News
BAYRY FAQ
What was Bayer’s price range in the past 12 months?
Bayer lowest stock price was $7.54 and its highest was $15.27 in the past 12 months.
What is Bayer’s market cap?
Bayer’s market cap is $55.73B.
When is Bayer’s upcoming earnings report date?
Bayer’s upcoming earnings report date is Nov 03, 2026 which is in 57 days.
How were Bayer’s earnings last quarter?
Bayer released its earnings results on Aug 04, 2026. The company reported $0.274 earnings per share for the quarter, beating the consensus estimate of $0.22 by $0.054.
Is Bayer overvalued?
According to Wall Street analysts Bayer’s price is currently Undervalued.
Does Bayer pay dividends?
Bayer pays a Annually dividend of $0.032 which represents an annual dividend yield of 0.23%. See more information on Bayer dividends here
What is Bayer’s EPS estimate?
Bayer’s EPS estimate is 0.14.
How many shares outstanding does Bayer have?
Bayer has 3,929,696,000 shares outstanding.
What happened to Bayer’s price movement after its last earnings report?
Bayer reported an EPS of $0.274 in its last earnings report, beating expectations of $0.22. Following the earnings report the stock price went up 2.477%.
Which hedge fund is a major shareholder of Bayer?
Currently, no hedge funds are holding shares in BAYRY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bayer Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$15.50 (8.39% Upside)
$15.50 (8.39% Upside)
Blogger Sentiment
Neutral
BAYRY Sentiment 50%
Sector Average 60%
Sector Average 60%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.9%
Last 30 Days ▲ 10.6%
Last 30 Days ▲ 10.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
71.03%
12-Months-Change
Fundamentals
Return on Equity
0.23%
Trailing 12-Months
Asset Growth
-0.71%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Bayer
Bayer Aktiengesellschaft, commonly known as Bayer AG, functions as a prominent global life sciences company through its various subsidiaries. Its extensive operations are strategically segmented into Pharmaceuticals, Consumer Health, and Crop Science. The Pharmaceuticals division concentrates on developing and marketing prescription medications, with key areas including cardiology and women's healthcare. It also offers specialized therapeutic solutions for oncology, hematology, and ophthalmology, alongside diagnostic imaging equipment, contrast agents, and advanced cell and gene therapies. Bayer's Consumer Health segment provides a wide array of non-prescription (over-the-counter) medicines, medical devices, medicated skincare items, and nutritional supplements. These self-care products address diverse health needs such as dermatology, dietary support, pain relief, cardiovascular risk prevention, digestive issues, allergy management, and cold and cough symptoms. The Crop Science division supports the agricultural sector with chemical and biological crop protection products, genetically enhanced plant traits, seeds, digital farming tools, and solutions for pest and weed control. This segment also manages the breeding, propagation, production, and specialized treatment of seeds, complemented by dedicated customer service for farmers. Bayer is actively involved in numerous strategic collaborations to bolster its research and development pipeline. These partnerships include an agreement with MD Anderson Cancer Center for oncology drug development, a research and licensing deal with Dewpoint Therapeutics, Inc. focused on novel treatments for cardiovascular and gynecological diseases, and collaborations with Exscientia Ltd, Foundation Medicine Inc., Evotec AG, and Arvinas Inc. Additionally, the company maintains strategic research alliances with the University of Oxford for gynecological therapies and with Kyoto University to discover potential new drugs for pulmonary conditions. The company’s products reach a broad market through various distribution channels, including wholesale partners, independent and chain pharmacies, supermarkets, online and other retail outlets, hospitals, and direct sales to agricultural producers. Bayer Aktiengesellschaft was established in 1863 and is headquartered in Leverkusen, Germany.
BAYRY Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple clear operational and strategic positives — steady group sales (+3%), EBITDA improvement (+7%), Crop Science margin expansion to 31%, strong growth in several Pharma assets (Nubeqa and Kerendia +66%), successful capital transactions (EUR 3bn Apollo investment and USD 5bn bond issuance) and a favorable U.S. Supreme Court ruling that materially strengthens litigation containment. Offsetting these strengths are meaningful near-term financial drains: negative free cash flow (‑EUR 2.7bn) driven by EUR 2.5bn in litigation payouts, elevated net debt in the near term (EUR 33.6bn), a 17% drop in Q2 core EPS due to normalization, Eylea sales down 27%, and continued legal and external-market risks. On balance, the highlights materially outweigh the lowlights given improving profitability, strategic progress, and decisive financing actions that reduce medium-term balance-sheet risk.View all BAYRY earnings summariesBAYRY Stock 12 Month Forecast
Average Price Target
$15.50
▲(8.39% Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.17% Mutual Funds
0.17% Other Institutional Investors
99.66% Public Companies and
Individual Investors